🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 12% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size
45 Servings
Fat/Fatty Acid Product Type
12% Evidence Coverage

Supplement Facts — Evidence Check

Calories
22 Calorie(s)
Total Fat
2 Gram(s) (4% DV)
Cholesterol
10 mg (4% DV)
Sodium
Total Carbohydrates
0.3 Gram(s) (1% DV)
Protein
0.6 Gram(s)
Marine Lipid Concentrate
2000 mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 600mg UL 3000mg

Other Ingredients

Gelatin Glycerin purified Water Mixed Tocopherols

Label Claims — Verification

All Other
Qualified Health
All Other (99% of products) Structure/Function (86% of products) Nutrient (79% of products) Qualified Health (13% of products) Approved Health (2% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

As a dietary supplement, adults 1-2 soft gels with each meal or as otherwise directed by your health care professional.

🧪 Formulation Notes

USP marine fish oils

No corn, soy, salt, yeast, gluten, milk & egg products, sugar, starch, or preservatives.

Additional Information

Also available in 180 count

GMP Quality Assured Earth Friendly

% Daily Value

Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. (See nutrition information for total fat, saturated fat, and cholesterol content).

Store in a cool, dry place and keep lid tightly closed.

PR 813

Product Details

UPC / SKU 7 68305 81390 8
DSLD Entry Date 2017-10-21
Product Type Fat/Fatty Acid
Form Softgel Capsule
DSLD ID 79643
Data Updated 2026-04-11

Research Evidence

495 Research Sources
56 Avg Quality Score
222 Meta Analysis
104 Clinical Trial
72 Rct
69 Systematic Review
11 Guideline
5 Cochrane Review
5 Regulatory Source
3 Narrative Review
1 Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
View all evidence for Omega 3 →

Compare Similar Products

View all Omega 3 products →